Astrazeneca Pharma India Ltd

A sustained decline has pushed Astrazeneca Pharma India Ltd to a fresh 52-week low of Rs 6606.3 on 22 Sep 2026, marking a significant 32.9% drop from its 52-week high of Rs 9850. The stock has underperformed its sector and the broader market, reflecting a complex interplay of valuation pressures and mixed financial signals.

A sustained decline has pushed Astrazeneca Pharma India Ltd to a fresh 52-week low of Rs 6610 on 18 Sep 2026, marking a significant 32.8% drop from its 52-week high of Rs 9850. This underperformance comes amid a broader market that is showing signs of resilience, highlighting a divergence that warrants closer examination.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 15 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

For the third consecutive session, Astrazeneca Pharma India Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 6,736 on 15 Sep 2026. This marks a significant 31.6% drop from its 52-week high of Rs 9,850, underscoring persistent selling pressure despite a broadly stable market backdrop.

For the second consecutive session, Astrazeneca Pharma India Ltd has slipped further, hitting a fresh 52-week low of Rs 6780 on 11 Sep 2026, extending its downward trajectory amid broader market weakness.

Astrazeneca Pharma India Ltd has edged to within a hair’s breadth of its 52-week low, closing at Rs 6,815.3 on 09 Sep 2026, marking a significant 25.15% decline over the past year. This downturn contrasts sharply with the broader market’s more modest losses, underscoring company-specific pressures that have weighed heavily on the stock.

Astrazeneca Pharma India Ltd has slipped to a fresh 52-week low of Rs 6815.3, extending its recent downward trajectory amid broader market weakness and company-specific pressures. This decline marks a significant 30.8% drop from its 52-week high of Rs 9850, underscoring the challenges facing the stock despite pockets of operational strength.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 04 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

For the eleventh consecutive session, Astrazeneca Pharma India Ltd has closed lower, culminating in a fresh 52-week low of Rs 6850 on 2 Sep 2026. This persistent decline has dragged the stock down by over 10% in less than three weeks, sharply underperforming both its sector and the broader market indices.

For the tenth consecutive session, Astrazeneca Pharma India Ltd has closed lower, culminating in a fresh 52-week low of Rs 6900.1 on 1 Sep 2026, marking an 8.91% decline over this period and a significant 30% drop from its 52-week high of Rs 9850.

For the ninth consecutive session, Astrazeneca Pharma India Ltd has closed lower, slipping to a fresh 52-week low of Rs 7,026.55 on 31 Aug 2026, marking an 8.15% decline over this losing streak and underperforming its sector by nearly 1%. This persistent slide contrasts sharply with broader market movements and raises questions about the underlying causes and prospects for the stock.

For the seventh consecutive session, Astrazeneca Pharma India Ltd has closed lower, slipping to a fresh 52-week low of Rs 7,085.05 on 27 Aug 2026, marking a near 7% decline over this losing streak and underscoring persistent selling pressure despite a broadly mixed market backdrop.

For the fifth consecutive session, Astrazeneca Pharma India Ltd has closed lower, slipping to a fresh 52-week low of Rs 7,174.05 on 25 Aug 2026, marking a 6.05% decline over this period and underscoring persistent selling pressure despite the broader market's mixed performance.

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

For the third consecutive session, Astrazeneca Pharma India Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 7,450 on 21 Aug 2026. This marks a 24.3% drop from its 52-week high of Rs 9,850, underscoring persistent selling pressure despite a broadly stable market backdrop.

Astrazeneca Pharma India Ltd has slipped to a fresh 52-week low of Rs 7,480.2 on 20 Aug 2026, extending a recent downtrend that has seen the stock underperform the broader market and its sector peers despite a backdrop of positive market momentum.

A sustained decline has pushed Astrazeneca Pharma India Ltd to a fresh 52-week low of Rs 7,590 on 19 Aug 2026, marking a notable underperformance against the broader market and its sector peers.

For the seventh consecutive session, Astrazeneca Pharma India Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 7,600 on 18 Aug 2026. This sustained downward momentum has dragged the stock down by nearly 7% over the past week, underperforming its sector and broader market indices.

For the sixth consecutive session, Astrazeneca Pharma India Ltd has closed lower, slipping to a fresh 52-week low of Rs 7,624.4 on 17 Aug 2026, marking a 6.61% decline over this period amid broader market weakness.